248 related articles for article (PubMed ID: 25192595)
1. Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: a preliminary analysis of the prothrombin fragment 1+2 levels.
Tajiri K; Sato A; Harunari T; Shimojo N; Yamaguchi I; Aonuma K
J Cardiol; 2015 Mar; 65(3):191-6. PubMed ID: 25192595
[TBL] [Abstract][Full Text] [Related]
2. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation.
Hitaka Y; Ogawa M; Zhang B; Goto S; Nagata Y; Morii J; Imaizumi S; Yasuda T; Matsumoto N; Matsunaga A; Saku K
J Cardiol; 2016 Dec; 68(6):529-535. PubMed ID: 26987789
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Neira V; Corbalán R; Pereira J; Panes O; Garayar B; Aizman A; Llevaneras S; Villarroel L
Rev Med Chil; 2016 Sep; 144(9):1103-1111. PubMed ID: 28060970
[TBL] [Abstract][Full Text] [Related]
4. Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population.
Kitagawa F; Ishii J; Hiramitsu S; Takahashi H; Okuyama R; Kawai H; Muramatsu T; Harada M; Motoyama S; Naruse H; Matsui S; Sarai M; Hayashi M; Watanabe E; Izawa H; Ozaki Y
Heart Vessels; 2017 May; 32(5):609-617. PubMed ID: 27796530
[TBL] [Abstract][Full Text] [Related]
5. Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement.
Hagii J; Tomita H; Metoki N; Tamai Y; Saito S; Shiroto H; Hitomi H; Kamada T; Seino S; Takahashi K; Sasaki S; Yasujima M; Okumura K
Thromb Res; 2016 Dec; 148():9-14. PubMed ID: 27764730
[TBL] [Abstract][Full Text] [Related]
6. Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
Ueno EI; Fujibayashi K; Sawaguchi J; Yasuda Y; Takano S; Fujioka N; Kawai Y; Fujita H; Tanaka Y; Kajinami K
J Thromb Thrombolysis; 2020 Aug; 50(2):371-379. PubMed ID: 32166540
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.
Nakano Y; Kondo T; Osanai H; Murase Y; Nakashima Y; Asano H; Ajioka M; Sakai K; Inden Y; Murohara T
J Cardiol; 2015 Mar; 65(3):185-90. PubMed ID: 25192594
[TBL] [Abstract][Full Text] [Related]
8. The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Li H; Zhang L; Xia M; Zhang C; Jiang T
Clin Appl Thromb Hemost; 2021; 27():10760296211044722. PubMed ID: 34559016
[TBL] [Abstract][Full Text] [Related]
9. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
[TBL] [Abstract][Full Text] [Related]
10. Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban.
Duarte RCF; Rios DRA; Figueiredo EL; Caiaffa JRS; Silveira FR; Lanna R; Alves LCV; Martins GL; Reis HJ; Reis EA; Ferreira CN; Sternick EB; Campos FMF; das Graças Carvalho M
J Thromb Thrombolysis; 2021 Jan; 51(1):47-57. PubMed ID: 32377955
[TBL] [Abstract][Full Text] [Related]
11. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.
Feinberg WM; Cornell ES; Nightingale SD; Pearce LA; Tracy RP; Hart RG; Bovill EG
Stroke; 1997 Jun; 28(6):1101-6. PubMed ID: 9183333
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
[TBL] [Abstract][Full Text] [Related]
13. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time.
Suzuki S; Otsuka T; Sagara K; Kano H; Matsuno S; Kato Y; Takai H; Uejima T; Oikawa Y; Nagashima K; Kirigaya H; Yajima J; Sawada H; Aizawa T; Yamashita T
Circ J; 2014; 78(3):763-6. PubMed ID: 24451650
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
[TBL] [Abstract][Full Text] [Related]
16. [Measurement of Prothrombin Fragment 1+2 for the Assessment of Anticoagulant Activity in Patients Treated with Warfarin or Non-vitamin K Antagonist Oral Anticoagulant].
Tomoda M; Yasaka M; Nakanishi Y; Takaguchi G; Nakamura A; Gotoh S; Kuwashiro T; Okada Y
Brain Nerve; 2017 May; 69(5):571-576. PubMed ID: 28479535
[TBL] [Abstract][Full Text] [Related]
17. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs.
Lynch AM; Ruterbories LK; Griffith EH; Hanel RM; Stablein AP; Brooks MB
J Vet Emerg Crit Care (San Antonio); 2021 Jan; 31(1):18-24. PubMed ID: 33118685
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
